title: [Treatment of chronic hepatitis C virus infection at the beginning of a new era].
abstract: After 2010 the therapy of chronic HCV infection entered a completely new era -  the era that is marked with the gradual introduction of the so-called directly acting antivirals into treatment schemes of this serious disease. The term directly acting antivirals (DAA) covers low-molecular substances that inhibit viral nonstructural proteins -  enzymes involved in the HCV replication cycle. At present, the first 2 representatives of DAA, Boceprevir and Telaprevir, have been approved for chronic HCV infection indication. The synoptic article pays the greatest attention to these 2 representatives, along with mentioning some other substances that are under later phases of clinical development and are likely to be approved in the near future.
authors.affiliation: Interní klinika 1. lékařské fakulty UK a VFVN Praha. petr.urbanek@uvn.cz
authors.forename: P
authors.initials: P
authors.lastname: Urbánek
mesh_terms: D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011392:Proline / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D011092:Polyethylene Glycols; C486464:telaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide; D007372:Interferons; D011392:Proline